MARKET
A Critical Sector Ripe for Consolidation
Targeting the Booming Biopharma Market
Growth in the biopharma CDMO market
Source: ResearchandMarkets
VC biotech investments in 2017 VS 2021
Source: Frost & Sullivan
Significant room for further consolidation
Source: WuXi Biologics 2019 Annual Result
– Highly fragmented market and large target reservoir.
– Substantial consolidation trend
(c. 40-60 transactions p.a.).
– More than 1,000 companies: 2/3 generating less than $50m revenues.
Source: WuXi Biologics 2019 Annual Result
– Highly fragmented market and large target reservoir.
– Substantial consolidation trend
(c. 40-60 transactions p.a.).
– More than 1,000 companies: 2/3 generating less than $50m revenues.
Strong Ramp-Up of Transaction Activity in the Biopharma CDMO Space – Expected to Continue
Source: WuXi Biologics 2019 Annual Result
CDMO Expertise Present Alongside the Whole Drug Development Chain
